Q1 2026 Agilent Technologies Inc Earnings Call Transcript
Key Points
- Agilent Technologies Inc (A) reported $1.8 billion in revenue for Q1 2026, growing 4.4% on a core basis, within their guidance range.
- The company experienced strong growth in its enterprise services business, which represents roughly 10% of total services revenue and has grown at a low double-digit CAGR.
- Agilent's Altura ultra inert column portfolio has seen significant adoption, with 50% of the top 20 biopharma companies ordering these columns since launch.
- The Pro IQ LCMS product line showed robust uptake, with growth of the single quad family exceeding 40% in the quarter.
- Agilent's Ignite operating system has delivered clear financial results, including doubling pricing realization and generating substantial procurement savings.
- The company faced a $10 million revenue impact due to a winter storm in the US, affecting logistics and shipping operations.
- Gross margins were down by 100 basis points year over year, primarily due to tariff headwinds.
- The LDG segment grew only 3%, below expectations, impacted by weather and softness in academia and government funding.
- The food business declined 4%, with strong growth outside China offset by previous stimulus benefits in China.
- Academia and government markets were down 8%, more than expected, with continued softness in US funding.
Ladies and gentlemen, thank you for joining us and welcome to the Q1 2026 Adjutant Technologies Inc. Earnings conference call. After today's prepared remarks, we will host a question-and-answer session.
If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press 9 to raise your hand and 6 to unmute. I will now hand the conference over to Tejas Savant, Vice President, Investor Relations. Tejas, please go ahead.
Thank you and welcome everyone to Adjulan's conference call for the first quarter of fiscal year 2026. With me on the line, our CEO Park McDonnell and CFO Adam Eanoff. Joining for the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group, Angelica Ryman, President of the Adjulan Cross Lab Group, and Mike Zeng, President of the Applied Market. Group. This presentation is being webcast live. The press release for our first quarter financial results, investor presentation, and information
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
